Ablynx N.v.

Boehringer Ingelheim International Gmbh

Gene Signal International Sa

Laboratoires Kôl

Jo Vercammen

Toon Laeremans

Cornelia Dorner-Ciossek

Gerald Beste

John Edward Park

Martin Lenter

Stefan Hoerer

Lothar Kussmaul

Joost Alexander Kolkman

Hilde Adi Pierrette Revets

Augustinus Antonius Maria Silvester Van Dongen

Antoine Ferry

Carla Missiaen

Katharina Zimmermann

Pascal Merchiers

Pascal Gerard Merchiers

Eric Viaud

Éric Viaud

Katharina Zimmerman

Augustinus Antonius Maria Silverster Van Dongen

A composition including a phosphorothioate oligonucleotide and at least one fatty acid and/or at least one emulsifying agent, where the composition is sterile and where the composition includes at least one agent including a thiol group and at least one phosphate compound, and the composition can be an ophthalmic composition. The present invention also relates to a method for obtaining the same and to the therapeutic use thereof.

Sterile formulation comprising a stable phosphorothioate oligonucleotide

The present invention relates to biological materials against HGF and more in particular to polypeptides, nucleic acids encoding such polypeptides; to methods for preparing such polypeptides; to host cells expressing or capable of expressing such polypeptides; to compositions and in particular to pharmaceutical compositions that comprise such polypeptides, for prophylactic, therapeutic or diagnostic purposes. In particular, the biological materials of the present invention inhibit binding of HGF to its receptor c-Met.

Sequences directed against hepatocyte growth factor (HGF) and polypeptides comprising the same for the treatment of cancers and/or tumors

The present invention relates to a composition comprising a phosphorothioate oligonucleotide and at least one fatty acid and/or at least one emulsifying agent, wherein said composition is sterile and wherein said composition comprises at least one agent comprising a thiol group and at least one phosphate compound, preferably said composition is an ophthalmic composition. The present invention also relates to a method for obtaining the same and to the therapeutic use thereof.

The invention relates to biparatopic A-beta binding polypeptides and, more specifically, to biparatopic A-beta binding polypeptides comprising at least two immunoglobulin single variable domains binding to different epitopes of A-beta. The invention also relates to specific sequences of such polypeptides, methods of their production, and methods of using them, including methods of treatment of diseases such as Alzheimer's Disease.

A-beta binding polypeptides

Nucleic acid molecules encoding A-beta binding polypeptides

Growing community of inventors

Sint-Pieters-Leeuw, Belgium

Jo Vercammen